Rasagiline is neuroprotective in an experimental
model of brain ischemia in the rat

Speiser Z, Mayk A, Litinetsky L, Fine T, Nyska A, Blaugrund E, Cohen S.
Department of Physiology and Pharmacology,
Sackler School of Medicine,
Tel Aviv University,
Ramat Aviv, Israel
J Neural Transm. 2006 Dec 21;


The neuroprotective effects of intravenous rasagiline were investigated in a rat model of stroke. Middle cerebral artery (MCA) occlusion was performed in male rats and the short- (neurological severity score [NSS], infarct size), intermediate- (cognition) and long-term (necrotic area) effects were assessed. A bolus (3 mg/kg) of rasagiline followed by a 3-h infusion (3 mg/kg/h), initiated immediately after MCA occlusion, reduced infarct size by 48.6% and NSS by 32.7% relative to saline treatment. Cognitive function, tested in a water maze 2-3 weeks after occlusion, also significantly improved compared with saline-treated controls. Necrotic brain area was 35-50% smaller with rasagiline than with saline following a single bolus dose. The single bolus rasagiline dose was as effective as a rasagiline bolus followed by rasagiline infusion in short-term outcomes. The neuroprotective effect of rasagiline was fully reproducible when administered at 2 h following occlusion but not after 4 h.

Rasagiline: structure
MAO-b inhibitors/PD
Anti-apoptotic activity
Alzheimer's disease: resources
Parkinson's disease: resources
Antioxidant strategies against aging
Antidepressant EMSAM (transdermal selegiline)
Rasagiline/Azilect: patient information leaflet (PDF)
Rasagiline (Azilect, Agilect) in early Parkinson's disease

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family